A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) (NCT06465186)
Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn: * If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver * About the safety of efinopegdutide and how well people tolerate it
Who can join: Review the eligibility criteria below.
Location: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149) — Chandler, Arizona
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (68 Sites)
Showing the first 25 of 68 sites.
- The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149) — Chandler, Arizona
- Arizona Clinical Trials ( Site 0158) — Flagstaff, Arizona
- The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120) — Peoria, Arizona
- The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 0111) — Tucson, Arizona
- California Liver Research Institute ( Site 0113) — Pasadena, California
- Acclaim Clinical Research ( Site 0137) — San Diego, California
- Velocity Clinical Research, Panorama City ( Site 0124) — Van Nuys, California
- Rocky Mountain Gastroenterology ( Site 0127) — Littleton, Colorado
- Synergy Healthcare ( Site 0118) — Bradenton, Florida
- Homestead Associates in Research, Inc. ( Site 0139) — Homestead, Florida
- Florida Research Institute ( Site 0116) — Lakewood Rch, Florida
- Floridian Clinical Research, LLC ( Site 0109) — Miami Lakes, Florida
- Southeast Clinical Research Center ( Site 0119) — Dalton, Georgia
- Delta Research Partners ( Site 0160) — Bastrop, Louisiana
- Louisiana Research Center ( Site 0161) — Shreveport, Louisiana
- Woodholme Gastroenterology Associates-Woodholme Gastroenterology Associates ( Site 0130) — Glen Burnie, Maryland
- Velocity Clinical Research Rockville ( Site 0143) — Rockville, Maryland
- Huron Gastroenterology ( Site 0102) — Ypsilanti, Michigan
- The Machuca Foundation ( Site 0115) — Las Vegas, Nevada
- Excel Clinical Research, LLC ( Site 0101) — Las Vegas, Nevada
- Southwest Gastroenterology Associates ( Site 0129) — Albuquerque, New Mexico
- Coastal Research Institute - Fayetteville ( Site 0159) — Fayetteville, North Carolina
- Lucas Research, Inc ( Site 0105) — Morehead City, North Carolina
- Texas Clinical Research Institute ( Site 0126) — Arlington, Texas
- Pinnacle Clinical Research ( Site 0104) — Austin, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-alcoholic Fatty Liver Disease
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Chula Vista, California
- Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk — St Louis, Missouri
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Birmingham, Alabama
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease — Chicago, Illinois
- The Olmsted NAFLD Epidemiology Study (TONES) — Rochester, Minnesota
Explore by condition: All Non-alcoholic Fatty Liver Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.